Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01309841
First received: March 4, 2011
Last updated: August 29, 2012
Last verified: August 2012

March 4, 2011
August 29, 2012
March 2011
August 2012   (final data collection date for primary outcome measure)
The primary efficacy endpoint is response (responder/non-responder) to study drug during Weeks 1 to 12, for at least 9 out of 12 weeks, and at least 3 out of the last 4 weeks. [ Time Frame: Up to 4 weeks ] [ Designated as safety issue: No ]
Responder is defined as having at least 3 SBMs/week with at least 1 SBM/week increase over baseline.
Response (responder/non-responder) to study drug during Weeks 1 to 4, where a responder is defined as having at least 3 Spontaneous Bowel Movements (SBMs)/week, with at least 1 SBM/week increase over baseline, for at least 3 out of the first 4 weeks. [ Time Frame: Up to 4 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01309841 on ClinicalTrials.gov Archive Site
  • Response (responder/non-responder) to study drug in the LIR subgroup during Weeks 1 to 12, for at least 9 out of 12 weeks and at least 3 out of the last 4 weeks. [ Time Frame: Up to 12 weeks ] [ Designated as safety issue: No ]
    Responder is defined as having at least 3 SBMs/week, with at least 1 SBM/week increase over baseline.
  • Time (in hours) to first post-dose laxation without the use of rescue laxatives within the previous 24 hours. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Mean number of days per week with at least 1 SBM during Weeks 1 to 12. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Response (responder/non-responder) to study drug in the LIR subgroup during Weeks 1 to 4, where a responder is defined as having at least 3 SBMs/week, with at least 1 SBM/week increase over baseline, for at least 3 out of the first 4 weeks. [ Time Frame: Up to 4 Weeks ] [ Designated as safety issue: No ]
  • Response (responder/non-responder) to study drug over the entire 12 week treatment period, where a responder is defined as having at least 3 SBMs/week, with at least 1 SBM/week increase over baseline, for at least 75% of the weeks. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Regularity during the first 4 weeks of treatment, where regularity is measured as the mean number of days per week with at least 1 SBM during Weeks 1 to 4. [ Time Frame: Up to 4 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain, including those patients that have inadequate response to laxative therapy (LIR).

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Opioid-Induced Constipation (OIC)
  • Drug: NKTR-118
    12.5 mg oral tablet once daily
  • Drug: NKTR-118
    25 mg oral tablet once daily
  • Drug: Placebo
    Oral tablet once daily
  • Experimental: 1
    Oral treatment
    Intervention: Drug: NKTR-118
  • Experimental: 2
    Oral treatment
    Intervention: Drug: NKTR-118
  • Placebo Comparator: 3
    Oral treatment
    Intervention: Drug: Placebo
Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014 Jun 19;370(25):2387-96. doi: 10.1056/NEJMoa1310246. Epub 2014 Jun 4.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
652
August 2012
August 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Provision of written informed consent prior to any study-specific procedures.
  • Men and women who are between the ages of ≥18 and <85 years.
  • Self-reported active symptoms of OIC at screening (<3 SBMs/week and experiencing ≥1 reported symptom of hard/lumpy stools, straining, or sensation of incomplete evacuation/anorectal obstruction in at least 25% of BMs over the previous 4 weeks); and Documented confirmed OIC (<3 SBMs/week on average over the 2-week OIC confirmation period.
  • Receiving a stable maintenance opioid regimen consisting of a total daily dose of 30 mg to 1000 mg of oral morphine, or equianalgesic amount(s) of 1 or more other opioid therapies for a minimum of 4 weeks prior to screening for non-cancer-related pain with no anticipated change in opioid dose requirement over the proposed study period as a result of disease progression.
  • Willingness to stop all laxatives and other bowel regimens including prune juice and herbal products throughout the 2-week OIC confirmation period and the 12-week treatment period, and to use only bisacodyl as rescue medication if a BM has not occurred within at least 72 hours of the last recorded BM.

Exclusion Criteria:

  • Patients receiving Opioid regimen for treatment of pain related to cancer.
  • History of cancer within 5 years from first study visit with the exception of basal cell cancer and squamous cell skin cancer.
  • Medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation.
  • Other issues to the gastrointestinal tract that could impose a risk to the patient.
  • Pregnancy or lactation.
Both
18 Years to 84 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Slovakia,   Australia,   Germany
 
NCT01309841
D3820C00004, 2011-001987-24
No
AstraZeneca
AstraZeneca
Not Provided
Study Director: Mark Sostek AstraZeneca Pharmaceuticals, Wilm DE
AstraZeneca
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP